gefitinib
Selected indexed studies
- Gefitinib. (Recent Results Cancer Res, 2018) [PMID:30069771]
- Gefitinib. (Profiles Drug Subst Excip Relat Methodol, 2014) [PMID:24794908]
- Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. (J Clin Oncol, 2020) [PMID:31682542]
_Worker-drafted node — pending editorial review._
Connections
gefitinib is a side effect of
Sources
- Gefitinib. (2018) pubmed
- Gefitinib. (2014) pubmed
- Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. (2020) pubmed
- FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. (2020) pubmed
- Gefitinib: An Updated Review of its Role in the Cancer Management, its Nanotechnological Interventions, Recent Patents and Clinical Trials. (2023) pubmed
- Gefitinib for the treatment of non-small-cell lung cancer. (2009) pubmed
- Gefitinib induces anoikis in cervical cancer cells. (2024) pubmed
- Pharmacokinetics of Gefitinib: Roles of Drug Metabolizing Enzymes and Transporters. (2017) pubmed
- Gefitinib (Iressa) trials in non-small cell lung cancer. (2003) pubmed
- Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. (2015) pubmed